Study reveals impact of age and variants on SARS-CoV-2 transmission: Insights from Toyama, Japan

  • 📰 NewsMedical
  • ⏱ Reading Time:
  • 69 sec. here
  • 3 min. at publisher
  • 📊 Quality Score:
  • News: 31%
  • Publisher: 71%

United Kingdom Headlines News

Study reveals impact of age and variants on SARS-CoV-2 transmission: Insights from Toyama, Japan COVID19 variants transmission age research Toyama Japan SARSCoV2 EpidemicWaves ContactTracing CDC_NCEZID

By Tarun Sai LomteJun 26 2023Reviewed by Benedette Cuffari, M.Sc. A recent study published in the journal Emerging Infectious Diseases evaluates infection rates of severe acute respiratory syndrome coronavirus 2 variants of concern among close contacts.

More recently, the SARS-CoV-2 Omicron variant has been shown to elicit a higher household secondary attack rate as compared to the previously dominant Alpha and Delta variants. The susceptibility and transmissibility of SARS-CoV-2 Delta and Omicron variants vary among studies, with children often considered to be more susceptible to these viral variants as compared to adults.

To this end, clinical data and activity history on COVID-19 cases and their contacts in Toyama Prefecture, Japan, during pre-VOC, Alpha, Delta, and Omicron periods were obtained through telephonic interviews. These periods spanned from July 1, 2020, to October 31, 2020, April 1, 2021, to April 30, 2021, July 3, 2021, to August 15, 2021, and January 3, 2022, to January 23, 2022, respectively.

Contacts were stratified into non-household and household contacts and were tested for COVID-19, irrespective of symptom status. Baseline characteristics of index cases and contacts were obtained for each of the four study periods. Of these, 358 contacts without polymerase chain reaction test results were excluded. Infection rates in the Omicron wave were 35% and 15.1% among household and non-household contacts, with 6.2- and 3.5-fold higher odds of infection than in the pre-VOC period, respectively, after adjusting for age, sex, symptoms, contact history, and household size.

 

Thank you for your comment. Your comment will be published after being reviewed.
Please try again later.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

 /  🏆 19. in UK

United Kingdom Latest News, United Kingdom Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

Unveiling the link: gut microbiome, diet, and SARS-CoV-2 infectionsUnveiling the link: gut microbiome, diet, and SARS-CoV-2 infections microbiome gutmicrobiome guthealth covid COVID19 SARSCoV2
Source: NewsMedical - 🏆 19. / 71 Read more »

Effectiveness of up-to-date COVID-19 vaccination in preventing SARS-CoV-2 infection among nursing home residents: study reveals 31.2% protectionEffectiveness of up-to-date COVID-19 vaccination in preventing SARS-CoV-2 infection among nursing home residents: study reveals 31.2% protection covid COVID19 SARSCov2 vaccine vaccination
Source: NewsMedical - 🏆 19. / 71 Read more »

Long-term protection unveiled: hybrid immunity guards against Omicron reinfectionsLong-term protection unveiled: hybrid immunity guards against Omicron reinfections researchsquare immunity omicron reinfection covid COVID19 SARSCoV2
Source: NewsMedical - 🏆 19. / 71 Read more »

Japan Sends Man to G7 Meeting on Women’s EmpowermentRepresentatives from each of the G7 nations gathered for a summit on gender equality and women’s empowerment. It made for an awkward photo-op: Japan’s representative to the gender equality meeting served as its chair—he was also its only man
Source: TIME - 🏆 93. / 53 Read more »

Japan jitters\n\t\t\tExpert insights, analysis and smart data help you cut through the noise to spot trends,\n\t\t\trisks and opportunities.\n\t\t\n\t\tJoin over 300,000 Finance professionals who already subscribe to the FT.
Source: FT - 🏆 113. / 51 Read more »

A blood microRNA classifier for the prediction of ICU mortality in COVID-19 patients: a multicenter validation study - Respiratory ResearchBackground The identification of critically ill COVID-19 patients at risk of fatal outcomes remains a challenge. Here, we first validated candidate microRNAs (miRNAs) as biomarkers for clinical decision-making in critically ill patients. Second, we constructed a blood miRNA classifier for the early prediction of adverse outcomes in the ICU. Methods This was a multicenter, observational and retrospective/prospective study including 503 critically ill patients admitted to the ICU from 19 hospitals. qPCR assays were performed in plasma samples collected within the first 48 h upon admission. A 16-miRNA panel was designed based on recently published data from our group. Results Nine miRNAs were validated as biomarkers of all-cause in-ICU mortality in the independent cohort of critically ill patients (FDR | 0.05). Cox regression analysis revealed that low expression levels of eight miRNAs were associated with a higher risk of death (HR from 1.56 to 2.61). LASSO regression for variable selection was used to construct a miRNA classifier. A 4-blood miRNA signature composed of miR-16-5p, miR-192-5p, miR-323a-3p and miR-451a predicts the risk of all-cause in-ICU mortality (HR 2.5). Kaplan‒Meier analysis confirmed these findings. The miRNA signature provides a significant increase in the prognostic capacity of conventional scores, APACHE-II (C-index 0.71, DeLong test p-value 0.055) and SOFA (C-index 0.67, DeLong test p-value 0.001), and a risk model based on clinical predictors (C-index 0.74, DeLong test-p-value 0.035). For 28-day and 90-day mortality, the classifier also improved the prognostic value of APACHE-II, SOFA and the clinical model. The association between the classifier and mortality persisted even after multivariable adjustment. The functional analysis reported biological pathways involved in SARS-CoV infection and inflammatory, fibrotic and transcriptional pathways. Conclusions A blood miRNA classifier improves the early prediction of fatal outcomes in critically
Source: BioMedCentral - 🏆 22. / 71 Read more »